Search Results Search Sort by RelevanceMost Recent Viewpoint Dec 2019 Genome Editing, Ethics, and Politics Isabel Gabel, PhD and Jonathan Moreno, PhD Genome editing raises old questions, but CRISPR arose in a political landscape that vastly differs from the early aughts. AMA J Ethics. 2019;21(12):E1105-1110. doi: 10.1001/amajethics.2019.1105. Art of Medicine Dec 2019 Sunset Antonio Yaghy, MD This image aims to promote reflection about patients’ feelings of sadness, despair, helplessness, and uncertainty upon being diagnosed. AMA J Ethics. 2019;21(12):E1103-1104. doi: 10.1001/amajethics.2019.1103. Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575. AMA Code Says Jul 2019 AMA Code of Medical Ethics’ Opinions Related to Unrepresented Patients Danielle Hahn Chaet, MSB The AMA Code of Medical Ethics discusses situations in which a surrogate is needed but not available to make health care decisions for a patient. AMA J Ethics. 2019;21(7):E600-602. doi: 10.1001/amajethics.2019.600. AMA Code Says Dec 2018 AMA Code of Medical Ethics’ Opinions Related to a Physician’s Power to Name Scott J. Schweikart, JD, MBE The Code offers guidance about delivering a diagnosis and promoting patients’ best interests when assigning names to patients’ conditions. AMA J Ethics. 2018;20(12):E1139-1142. doi: 10.1001/amajethics.2018.1139. Medicine and Society Jun 2016 Ethical and Epidemiological Dimensions of Labeling Psychosis Risk Cheryl M. Corcoran, MD Although the stigma of the psychosis risk label can cause harm, the label can also confer benefit and provides an explanatory framework for symptoms. AMA J Ethics. 2016;18(6):633-642. doi: 10.1001/journalofethics.2016.18.6.msoc2-1606. Podcast Dec 2019 Ethics Talk: How Do We Prepare for Human Gene Editing? Dr Sean C. McConnell provides an introduction to gene editing, and Scott J. Schweikart discusses what prudent governance requires. Art of Medicine Feb 2020 Risks, Benefits, and Conundrums of Cancer Screening Nick Love, PhD A patient’s story represents an ethical dilemma of cancer screening: it can save lives but generates diagnostic morbidity and incurs costs. AMA J Ethics. 2020;22(2):E164-165. doi: 10.1001/amajethics.2020.164. Case and Commentary Feb 2022 ¿Cómo deben los médicos determinar la disposición de un paciente traumatizado para regresar al trabajo? Tabitha E. H. Moses, MS and Arash Javanbakht, MD AMA J Ethics. 2022;E111-119. doi: 10.1001/amajethics.2022.111. Podcast Feb 2022 Author Interview: “How Should Clinicians Determine a Traumatized Patient’s Readiness to Return to Work?” Tabitha E. H. Moses, MS joins Ethics Talk to discuss her article, coauthored with Dr Arash Javanbakht: “How Should Clinicians Determine a Traumatized Patient’s Readiness to Return to Work?” Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
Viewpoint Dec 2019 Genome Editing, Ethics, and Politics Isabel Gabel, PhD and Jonathan Moreno, PhD Genome editing raises old questions, but CRISPR arose in a political landscape that vastly differs from the early aughts. AMA J Ethics. 2019;21(12):E1105-1110. doi: 10.1001/amajethics.2019.1105.
Art of Medicine Dec 2019 Sunset Antonio Yaghy, MD This image aims to promote reflection about patients’ feelings of sadness, despair, helplessness, and uncertainty upon being diagnosed. AMA J Ethics. 2019;21(12):E1103-1104. doi: 10.1001/amajethics.2019.1103.
Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575.
AMA Code Says Jul 2019 AMA Code of Medical Ethics’ Opinions Related to Unrepresented Patients Danielle Hahn Chaet, MSB The AMA Code of Medical Ethics discusses situations in which a surrogate is needed but not available to make health care decisions for a patient. AMA J Ethics. 2019;21(7):E600-602. doi: 10.1001/amajethics.2019.600.
AMA Code Says Dec 2018 AMA Code of Medical Ethics’ Opinions Related to a Physician’s Power to Name Scott J. Schweikart, JD, MBE The Code offers guidance about delivering a diagnosis and promoting patients’ best interests when assigning names to patients’ conditions. AMA J Ethics. 2018;20(12):E1139-1142. doi: 10.1001/amajethics.2018.1139.
Medicine and Society Jun 2016 Ethical and Epidemiological Dimensions of Labeling Psychosis Risk Cheryl M. Corcoran, MD Although the stigma of the psychosis risk label can cause harm, the label can also confer benefit and provides an explanatory framework for symptoms. AMA J Ethics. 2016;18(6):633-642. doi: 10.1001/journalofethics.2016.18.6.msoc2-1606.
Podcast Dec 2019 Ethics Talk: How Do We Prepare for Human Gene Editing? Dr Sean C. McConnell provides an introduction to gene editing, and Scott J. Schweikart discusses what prudent governance requires.
Art of Medicine Feb 2020 Risks, Benefits, and Conundrums of Cancer Screening Nick Love, PhD A patient’s story represents an ethical dilemma of cancer screening: it can save lives but generates diagnostic morbidity and incurs costs. AMA J Ethics. 2020;22(2):E164-165. doi: 10.1001/amajethics.2020.164.
Case and Commentary Feb 2022 ¿Cómo deben los médicos determinar la disposición de un paciente traumatizado para regresar al trabajo? Tabitha E. H. Moses, MS and Arash Javanbakht, MD AMA J Ethics. 2022;E111-119. doi: 10.1001/amajethics.2022.111.
Podcast Feb 2022 Author Interview: “How Should Clinicians Determine a Traumatized Patient’s Readiness to Return to Work?” Tabitha E. H. Moses, MS joins Ethics Talk to discuss her article, coauthored with Dr Arash Javanbakht: “How Should Clinicians Determine a Traumatized Patient’s Readiness to Return to Work?”